HCW Biologics Inc. (HCWB)
NASDAQ: HCWB · Real-Time Price · USD
0.765
-0.182 (-19.24%)
Nov 21, 2024, 12:19 PM EST - Market open
HCW Biologics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 3.5 | 2.84 | 6.72 | - | 4.1 | - |
| Revenue Growth (YoY) | 22.27% | -57.72% | - | - | - | - |
| Cost of Revenue | 7.61 | 7.53 | 4.14 | - | - | - |
| Gross Profit | -4.12 | -4.69 | 2.59 | - | 4.1 | - |
| Selling, General & Admin | 24.28 | 13.44 | 8.41 | 5.3 | 2.75 | 2.08 |
| Research & Development | 7.39 | 7.59 | 9.25 | 8.07 | 7.17 | 5.28 |
| Operating Expenses | 32.97 | 21.03 | 17.67 | 13.37 | 9.92 | 7.37 |
| Operating Income | -37.09 | -25.72 | -15.08 | -13.37 | -5.82 | -7.37 |
| Interest Expense | -0.38 | -0.28 | -0.13 | - | - | - |
| Interest & Investment Income | - | - | - | - | 0.02 | 0.07 |
| Other Non Operating Income (Expenses) | -0.13 | 0.74 | 0.49 | -0.06 | - | - |
| EBT Excluding Unusual Items | -37.6 | -25.26 | -14.71 | -13.43 | -5.8 | -7.29 |
| Gain (Loss) on Sale of Investments | 0.26 | 0.26 | -0.19 | - | - | - |
| Other Unusual Items | - | - | - | 0.57 | - | - |
| Pretax Income | -37.33 | -24.99 | -14.9 | -12.86 | -5.8 | -7.29 |
| Net Income | -37.33 | -24.99 | -14.9 | -12.86 | -5.8 | -7.29 |
| Preferred Dividends & Other Adjustments | - | - | - | - | 1.27 | 0.49 |
| Net Income to Common | -37.33 | -24.99 | -14.9 | -12.86 | -7.07 | -7.78 |
| Shares Outstanding (Basic) | 38 | 36 | 36 | 19 | 5 | 4 |
| Shares Outstanding (Diluted) | 38 | 36 | 36 | 19 | 5 | 4 |
| Shares Change (YoY) | 5.37% | 0.30% | 90.84% | 296.07% | 10.56% | - |
| EPS (Basic) | -0.99 | -0.70 | -0.42 | -0.69 | -1.49 | -1.82 |
| EPS (Diluted) | -0.99 | -0.70 | -0.42 | -0.69 | -1.49 | -1.82 |
| Free Cash Flow | - | -28.72 | -20.66 | -11.02 | -10.62 | -8.23 |
| Free Cash Flow Per Share | - | -0.80 | -0.58 | -0.59 | -2.24 | -1.92 |
| Gross Margin | -117.76% | -165.02% | 38.48% | - | 100.00% | - |
| Operating Margin | -1060.88% | -904.96% | -224.32% | - | -142.07% | - |
| Profit Margin | -1067.83% | -879.52% | -221.67% | - | -172.54% | - |
| Free Cash Flow Margin | - | -1010.51% | -307.36% | - | -258.99% | - |
| EBITDA | -36.75 | -24.91 | -14.49 | -12.82 | -5.25 | -6.94 |
| EBITDA Margin | - | - | -215.55% | - | -128.10% | - |
| D&A For EBITDA | 0.34 | 0.81 | 0.59 | 0.54 | 0.57 | 0.42 |
| EBIT | -37.09 | -25.72 | -15.08 | -13.37 | -5.82 | -7.37 |
| EBIT Margin | - | - | -224.32% | - | -142.07% | - |
| Revenue as Reported | 0.57 | - | - | - | 4.1 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.